Dr. Rama Devi Nayini M.D.

Recommended Articles

• How Astrophysics Could Transform the Treatment of Cystic Fibrosis and Other Rare Diseases

  Cystic fibrosis is a genetic disease that mainly affects the lungs, liver, pancreas, intestines, reproductive organs, and sinuses. It causes thick and sticky mucus to accumulate and clog the lungs, making it difficult to breathe and resulting in persistent lung infections and lung damage. The...

• What Are the Treatment Options Available for Bronchitis?

  Bronchitis is a condition that occurs due to the inflammation of the bronchial tubes. There are two types of bronchitis: acute and chronic. Acute bronchitis is usually caused by a viral infection or in some cases, 10 percent by a bacterial infection. Chronic bronchitis, on the other hand, is a...

• Are There any Risk Factors for Bronchitis?

  Bronchitis is a condition which occurs due to the inflammation of bronchial tubes. There are two types of bronchitis; acute bronchitis and chronic bronchitis.There are various factors involved in the development of bronchitis. The lifestyle of a person and his or her medical history are the main...

• What Can Cause Shortness of Breath (Dyspnea)?

  Shortness of breath is defined as the feeling of inability to breathe normally, hence producing a troublesome sensation. Such breathlessness is a distinct issue in every affected individual. Typically, if in an event of modest labor or any unexpected situation leads to a shortness of breath, it is...

• Everything About Bacterial Pneumonia: Its Causes, Symptoms, Diagnosis, and Management

  What Is Pneumonia?Pneumonia is a tenderness or inflammation of the lung, upsetting the air sacs (alveoli) predominantly. It is normally caused by infectious elements such as bacteria and viruses. Risk components of pneumonia are comprised of other lung-linked diseases, such as COPD, asthma, heart...

• FDA Approves Orkambi to Treat Young Children with Cystic Fibrosis

  Orkambi is an oral drug developed by Vertex Pharmaceuticals and approved by the United States Food and Drug Administration (FDA) for the treatment of cystic fibrosis (CF) in certain patient groups. It is the second drug to be approved for use in patients with CF, after Kalydeco. ...